After an infection, experts give advice on how to use eye creams correctly.

Published Date: 08 Mar 2023

Following a major outbreak involving the use of tear drops in 13 US states, experts are offering advice on how to protect dry eyes.

Read Full News

Latest News

What Caused the Pigmented Spot on Teen Boy's Eye?

Authors discuss how best to diagnose and manage him, given the absence of any symptoms

The HCPFive: Top News for Healthcare Providers from the Week of 01/25 HCPLive Editorial Staff

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

FDA News Recap: Novel Drug Approvals in First Half of 2026

FDA News Recap: Novel Drug Approvals in First Half of 2026

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

FDA Issues Third Reproxalap CRL for Dry Eye Disease

FDA Issues Third Reproxalap CRL for Dry Eye Disease

Todays Updates

Conference Preview: 2026 GOLD International COPD Conference Tim Smith

HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.

7 Pulmonology Headlines You Missed in October

7 Pulmonology Headlines You Missed in October

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

Q&A: Why 70% of COPD Goes Undiagnosed, With Alvar Agustí, MD

Q&A: Why 70% of COPD Goes Undiagnosed, With Alvar Agustí, MD

Mucus Plugs in COPD: Prevalence, Exacerbations, Mortality Risk

Mucus Plugs in COPD: Prevalence, Exacerbations, Mortality Risk

Analyzing Inebilizumab’s Durable Benefit in MINT Open-Label Extension Marco Meglio

Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.

Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162 Marco Meglio

uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.

Todays Updates

Conference Preview: 2026 GOLD International COPD Conference Tim Smith

HCPLive previews GOLD 2026 in Philadelphia, November 5-6, with sessions on the 2027 GOLD Report, mucus plugging, and exacerbations, plus expert interviews.

7 Pulmonology Headlines You Missed in October

7 Pulmonology Headlines You Missed in October

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

Nasal mRNA ETH47 Lowers Rhinovirus Load in Asthma Challenge Study

Q&A: Why 70% of COPD Goes Undiagnosed, With Alvar Agustí, MD

Q&A: Why 70% of COPD Goes Undiagnosed, With Alvar Agustí, MD

Mucus Plugs in COPD: Prevalence, Exacerbations, Mortality Risk

Mucus Plugs in COPD: Prevalence, Exacerbations, Mortality Risk

Analyzing Inebilizumab’s Durable Benefit in MINT Open-Label Extension Marco Meglio

Richard Nowak, MD, director of the Yale Myasthenia Gravis Clinic and global principal investigator of the MINT trial, discusses open-label extension findings for inebilizumab, a CD19-directed B cell depleting therapy, in generalized myasthenia gravis.

Final Results Reported for EPISOD1 Trial of SOD1-ALS Gene Therapy AMT-162 Marco Meglio

uniQure presented final safety and biomarker results from the discontinued EPISOD1 trial of AMT-162, an investigational gene therapy for SOD1-associated ALS.

Latest News

Authors discuss how best to diagnose and manage him, given the absence of any symptoms

Stay updated with the latest healthcare breakthroughs, including new phase 2 obesity data, FDA actions, and new hematology guidelines in this week’s essential news roundup.

FDA News Recap: Novel Drug Approvals in First Half of 2026

The HCPFive: Top News for Healthcare Providers from the Week of 04/05

Tepezza OBI Achieves Proptosis Reduction in Thyroid Eye Disease in Phase 3 Trial

FDA Issues Third Reproxalap CRL for Dry Eye Disease

News All Time

Consider This Before Cataract Surgery; Grant Rule: What's Next? CDC Nominee Grilled

MedPage Today reporters offer further insights into recently covered topics

New Agents for AMD Preserve Vision, Dramatically Reduce Treatment Burden

Bispecific antibody fares well against faricimab, two gene therapies extend treatment intervals

Vision Benefits in GA With Complement Inhibitor, Regardless of AMD, Anti-VEGF

Largest effects seen in eyes with GA and AMD, dual treatment with pegcetacoplan, VEGF inhibitor

Anti-VEGF Continuous Delivery Device Preserves Vision, Retinal Anatomy in DME

Similar results in patients who had port delivery system for 4 years or switched after 64 weeks

Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration

Stable vision and retinal anatomy for up to 5 years, no supplemental therapy for up to 2 years

Drugs for Dry AMD Linked to Thickening of Retinal Nerve

More questions than answers, including whether the thickening is neuroprotective or pathologic

Stem Cell Therapy for GA Shows Early Evidence of Vision Gains, Retina Preservation

ASP7317 may offer potential to improve vision and repair retina, not just slow down atrophy

Branded Bevacizumab Approved for Wet AMD

Approval follows 20 years of off-label use of compounded formulations of the VEGF inhibitor

Use of PDE5 Inhibitor Tied to Increased Glaucoma Risk

Findings add to existing evidence linking the drug class to ophthalmic conditions

Medicare's Paying Less for Cataract Surgery. Ophthalmologists Are Turning to Lasers.

— Doctors typically charge $1,000 to $3,000 per eye for use of the laser

Medicare Is Paying Less for Cataract Surgery

Medicare pays doctors about $520 for a standard cataract procedure, down about 20% in the past decade.

EyePoint's Drug for Age-related Eye Disease Fails Late-stage Trial, Shares Tank

EyePoint said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision ⁠from causes unrelated to the targeted disease, sending its...

Massage Matches Clinic Probing for Infant Tear Duct Blockage

Gently massaging the tear sacs of infants with blocked tear ducts may be as effective as clinic-based probing for clearing tearing and discharge, a noninferiority trial finds.

Can Dexamethasone Drops Prevent Retinal Disease in Preemies?

Dexamethasone eye drops administered in premature infants with early-stage retinal disease appear to reduce the odds of progression to treatment-requiring disease.

Urinary Drug Tadalafil Linked to Glaucoma Risk

Men taking tadalafil for lower urinary tract symptoms face a 22% higher risk of developing glaucoma than those who do not take the drug, a new study finds.

Study Links Uveitis to Higher Risk for Psychiatric Illness

Noninfectious uveitis is linked to higher rates of psychiatric comorbidities, with Black patients most affected, a new study finds.

Recommended News For You

Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer

ctDNA-Guided Adjuvant Therapy Cuts Bladder Cancer Costs

After three years, responses to mounetuzumab in follicular lymphoma are still stable.

Subcutaneous Toripalimab Matches IV Formulation in NSCLC

Formaldehyde releasers found in common personal care products used especially by Black and Latina women

Studies point to redlining as a 'perfect storm' for breast cancer

Since 2000, the outlook for multiple myeloma has improved.

Recommended Articles For You

Cerebrospinal Fluid Metabolite Biomarkers in Central Nervous System Tumor Monitoring: A New Frontier 

Emerging Therapies Through Artificial Bone Marrow Niche Engineering 

Exposure Modeling in Hematologic Malignancies: Advances, Clinical Implications, and Future Directions 

Understanding Sickle Cell Anemia: Causes, Symptoms, and Treatment Options  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers investigate risk of developing multiple primary cancers after surviving bowel cancer

2.

When a Groundbreaking Cancer Therapy Causes Cancer.

3.

An inadvertent loss of weight may be an indication to consult a physician, according to research.

4.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

5.

Extended lymphadenectomy has no survival benefit in patients with muscle-invasive bladder cancer.

1.

Digital Oral Oncology Care Pathways

2.

Bone Marrow Niche Dysregulation in Hematologic Disorders

3.

Exploring the Causes and Treatments of Thrombocytopenia: A Comprehensive Guide

4.

Radiation in Oncology: Advances, Applications, and Accessibility

5.

Cancer Care Access Across Communities: Epidemiology, Clinical Insights, and Emerging Solutions

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Teaching Coagulation Pathways Through Interactive Thrombin Generation Models

2.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

3.

The Role of Platelets in Normal Blood Clotting

4.

Understanding the Difference Between Iron Deficiency and Other Types of Anemia

5.

Updates on Standard V/S High Risk Myeloma Treatment


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot